Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a meta-analysis confirms colchicine reduces recurrent cardiovascular events in secondary prevention; a prospective multicenter study defines zero-hour thresholds for a point-of-care high-sensitivity troponin I assay to rapidly rule-out/in myocardial infarction; and an integrative human genetic–multiomics–preclinical study identifies CALB2 as a causal biomarker and therapeutic target for abdominal aortic aneurysm with repurposable drugs. These c
Summary
Three impactful cardiology studies stood out today: a meta-analysis confirms colchicine reduces recurrent cardiovascular events in secondary prevention; a prospective multicenter study defines zero-hour thresholds for a point-of-care high-sensitivity troponin I assay to rapidly rule-out/in myocardial infarction; and an integrative human genetic–multiomics–preclinical study identifies CALB2 as a causal biomarker and therapeutic target for abdominal aortic aneurysm with repurposable drugs. These collectively advance anti-inflammatory therapy, acute diagnostics, and target discovery in vascular disease.
Research Themes
- Inflammation-targeted secondary prevention
- Point-of-care diagnostics in acute coronary care
- Multiomics-driven therapeutic targets in vascular disease
Selected Articles
1. Colchicine for secondary prevention of vascular events: a meta-analysis of trials.
This study-level meta-analysis of nine randomized trials (n=30,659) shows that colchicine reduces the composite of cardiovascular death, MI, or stroke by 12%, driven largely by lower MI risk. Gastrointestinal hospitalizations increased, but pneumonia, cancer, and non-cardiovascular death did not.
Impact: Aggregating contemporary RCTs provides a decisive estimate supporting colchicine for secondary prevention, aligning inflammation control with event reduction.
Clinical Implications: Clinicians can consider low-dose colchicine as an adjunct for secondary prevention in atherosclerotic disease, with counseling on gastrointestinal intolerance and monitoring for adverse effects.
Key Findings
- Composite of CV death/MI/stroke reduced by 12% (RR 0.88, 95% CI 0.81–0.95).
- Myocardial infarction reduced (RR 0.84, 95% CI 0.73–0.97); stroke showed a nonsignificant trend (RR 0.90).
- Gastrointestinal hospitalizations increased (RR 1.35) without increases in pneumonia, new cancers, or non-CV death.
Methodological Strengths
- Study-level meta-analysis restricted to randomized controlled trials.
- Large aggregate sample size (n=30,659) with intention-to-treat analyses.
Limitations
- Heterogeneity in colchicine dosing, populations, and background therapies; fixed-effect model may underweight between-study variability.
- Safety signal limited to GI hospitalizations; individual patient data were not analyzed.
Future Directions: Define optimal dose, duration, and patient selection (e.g., residual inflammatory risk) and evaluate interactions with contemporary lipid-lowering and antithrombotic regimens.
BACKGROUND AND AIMS: Randomized trials of colchicine in secondary prevention of atherosclerotic cardiovascular disease have shown mixed results. METHODS: A systematic review and study-level meta-analysis of randomized controlled trials was performed comparing colchicine vs no colchicine in a secondary-prevention atherosclerotic cardiovascular disease population. A fixed-effect inverse variance model was applied using the intention-to-treat population from the included trials. The primary outcome was the composite of cardiovascular death, myocardial infarction, or stroke. RESULTS: Nine trials, including 30 659 patients (colchicine 15 255, no colchicine 15 404) with known coronary artery disease or stroke, were included. Compared with no colchicine, patients randomized to colchicine had a relative risk (RR) of 0.88 [95% confidence interval (CI) 0.81-0.95, P = .002] for the primary composite outcome, including a RR of 0.94 for cardiovascular death (95% CI 0.78-1.13, P = .5), a RR of 0.84 for myocardial infarction (95% CI 0.73-0.97, P = .016), and a RR of 0.90 for stroke (95% CI 0.80-1.02, P = .09). Colchicine was associated with a RR of 1.35 for hospitalization for gastrointestinal events (95% CI 1.10-1.66, P = .004) with no increase in hospitalization for pneumonia, newly diagnosed cancers, or non-cardiovascular death. CONCLUSIONS: In patients with prior coronary disease or stroke, colchicine reduced the composite of cardiovascular death, myocardial infarction, or stroke by 12%.
2. Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics.
Integrative proteome-wide Mendelian randomization, multiomics, and mouse validation identify CALB2 as a causal biomarker/target for AAA, predominantly expressed in adipose mesothelial cells. Pharmacologic inhibition via lenalidomide or genistein attenuated aneurysm progression in preclinical models.
Impact: Identifies a genetically supported target with preclinical efficacy and repurposable agents for a disease lacking medical therapy.
Clinical Implications: CALB2 may serve as a circulating biomarker and a therapeutic target for AAA; lenalidomide/genistein warrant early-phase clinical testing while monitoring on-target and off-target effects.
Key Findings
- Proteome-wide Mendelian randomization supports a causal effect of CALB2 on AAA risk.
- CALB2 is predominantly expressed in adipose tissue mesothelial cells by single-cell/spatial transcriptomics.
- Inhibiting CALB2 attenuated AAA progression in ApoE−/− AngII mouse models; lenalidomide and genistein were effective candidates.
Methodological Strengths
- Triangulation: genetic causality (MR), colocalization, and phenome-wide analyses combined with multiomics localization.
- In vivo functional validation and druggability assessment with repurposing candidates.
Limitations
- Preclinical efficacy is limited to murine models; human therapeutic translatability remains unproven.
- MR assumptions (e.g., no horizontal pleiotropy) and potential off-target effects of repurposed agents require careful testing.
Future Directions: Validate circulating CALB2 as a biomarker in human AAA cohorts, develop selective CALB2 modulators, and initiate phase I/II trials of repurposed agents with mechanistic endpoints.
BACKGROUND: Abdominal aortic aneurysm (AAA) is a clinical life-threatening issue. No pharmacological treatments are currently approved for the prevention and treatment of AAA. Therefore, identifying novel biomarkers and therapeutic targets is crucial for improving AAA management and outcomes. METHODS: To identify plasma proteins with potential causal effects on AAA, we integrated genetic evidence from proteome-wide Mendelian randomization, genetic correlation, and colocalization analysis. The role of identified proteins in AAA was further explored through the phenome-wide association study and mediation analysis. Multiomics data analysis, including bulk RNA sequencing, single-cell/single-nucleus RNA sequencing, and spatial transcriptomics, was employed to characterize the expression patterns of these proteins. Experimental validation was performed using an AAA model in apolipoprotein E-deficient mice infused with angiotensin II. Druggability analysis was conducted to identify drug candidates, which were tested in preclinical mouse models. RESULTS: CALB2 (calbindin 2) was identified as having a causal effect on AAA and may influence the progression of AAA through the regulation of lipid metabolism. Multiomics analysis revealed that CALB2 is predominantly expressed in the mesothelial cells of adipose tissues. Inhibition of CALB2 in an AAA mouse model alleviated AAA progression. Druggability analysis identified lenalidomide and genistein as potential therapeutic candidates, and experiments confirmed their efficacy in preventing AAA development. CONCLUSIONS: This study identifies CALB2 as being associated with an increased risk of AAA and suggests that i might be a novel biomarker and therapeutic molecule for AAA management. Lenalidomide and genistein hold promising potential as treatments for patients with AAA.
3. Zero-hour thresholds to risk stratify patients for acute myocardial infarction using a point-of-care high-sensitivity troponin assay.
In 967 ED patients with suspected ACS, zero-hour point-of-care hs-cTnI thresholds of <5 ng/L (100% sensitivity) and <8 ng/L (NPV >99.5%) effectively identify low-risk patients, while >25 and >60 ng/L stratify high-risk patients (PPV 50% and 68.3%).
Impact: Provides actionable, assay-specific zero-hour thresholds enabling rapid rule-out/in where lab access is limited, accelerating safe disposition and resource allocation.
Clinical Implications: Emergency departments can implement <5 or <8 ng/L to safely rule out MI at presentation and use >25 and >60 ng/L to prioritize invasive evaluation or observation, particularly useful in rural or high-throughput settings.
Key Findings
- MI prevalence was 5.6% among 967 suspected ACS patients.
- <8 ng/L achieved NPV >99.5% with sensitivity 94.4% (95% CI 84.6–98.8%); <5 ng/L achieved 100% sensitivity (95% CI 93.4–100.0%).
- High-risk thresholds: >25 ng/L yielded PPV 50% (95% CI 38.0–62.0%), and >60 ng/L PPV 68.3% (95% CI 51.9–81.9%).
Methodological Strengths
- Prospective, multicenter enrollment with prespecified diagnostic performance metrics.
- Assay-specific thresholds for a widely available point-of-care platform.
Limitations
- Observational design without randomized management based on thresholds; potential spectrum and selection bias.
- Single assay platform; external validation across devices and populations is needed.
Future Directions: Prospective implementation trials comparing zero-hour POC hs-cTnI strategies vs standard pathways, and validation across diverse populations and platforms.
AIMS: High-sensitivity cardiac troponin (hs-cTn) assays are crucial in assessing suspected myocardial infarction (MI). International recommendations recommend evaluating new assays to identify metrics for clinical use. Our primary aim was to identify patients at low risk of index MI using a point of care hs-cTnI (Abbott i-STAT® hs-TnI) assay at presentation. We also sought to examine the diagnostic accuracy of a single value for identifying patients at high risk for acute MI. METHODS AND RESULTS: This prospective multicentre observational trial enrolled patients with suspected acute coronary syndrome. Nine hundred sixty-seven patients had blood drawn on presentation to the emergency department for hs-cTnI measurement. The primary outcome was index MI including type one or two non-ST segment elevation MI. Diagnostic accuracy statistics were calculated at a range of hs-cTnI values. 5.6% of patients met the criteria for MI. A cut-off <8 ng/L was the highest threshold to achieve an negative predictive value >99.5%. This threshold had a sensitivity of 94.4% (95% CI: 84.6-98.8%). An hs-cTnI concentration of <5 ng/L provided a sensitivity of 100% (95% CI: 93.4-100.0%). For identifying high-risk patients, the positive predictive value (PPV) is the highest at a troponin of >60 ng/L (68.3%, 95% CI: 51.9-81.9%). A PPV of 50% (95% CI: 38.0-62.0%) is achieved at a cut-off of >25 ng/L. CONCLUSION: This study identified two hs-cTnI thresholds (<5 ng/L or <8 ng/L) to identify patients at low risk and two thresholds (>25 ng/L and >60 ng/L) to identify patients at high risk for MI. Our findings provide promise for improving care in rural and inner-city medical settings.